Targeting apoC-III and ANGPTL3 in the treatment of hypertriglyceridemia

References

• Ford ES, Li C, Zhao G, et al. Hypertriglyceridemia and its pharmacologic treatment among US adults. Arch Intern Med. 2009 Mar 23;169(6):572–578.
   PubMedGoogle Scholar
• Klop B, Elte JWF, Cabezas MC. Dyslipidemia in obesity: mechanisms and potential targets. Nutrients. 2013;5(4):1218–1240.
   PubMed Web of Science ®Google Scholar
• Björnson E, Adiels M, Taskinen M-R, et al. Kinetics of plasma triglycerides in abdominal obesity. Curr Opin Lipidol. 2017;28(1):11–18.
   PubMed Web of Science ®Google Scholar
• Liu J, Zeng -F-F, Liu Z-M, et al. Effects of blood triglycerides on cardiovascular and all-cause mortality: a systematic review and meta-analysis of 61 prospective studies. Lipids Health Dis. 2013;12: 159.
   Web of Science ®Google Scholar
• Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation. 2007 Jan 30;115(4):450–458.
   PubMed Web of Science ®Google Scholar
• Triglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors Collaboration, Sarwar N, Sandhu M, et al. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet. 2010 May 08;375(9726):1634–1639.
   PubMed Web of Science ®Google Scholar
• Rosenson RS, Davidson MH, Hirsh BJ, et al. Genetics and causality of triglyceride-rich lipoproteins in atherosclerotic cardiovascular disease. J Am Coll Cardiol. 2014 Dec 16;64(23):2525–2540.
   PubMed Web of Science ®Google Scholar
• Pare G, Anand SS. Mendelian randomisation, triglycerides, and CHD. Lancet. 2010 May 08;375(9726):1584–1586.
   PubMed Web of Science ®Google Scholar
• Hassing HC, Surendran RP, Mooij HL, et al. Pathophysiology of hypertriglyceridemia. Biochim Biophys Acta. 2012 May 01;1821(5):826–832.
   PubMed Web of Science ®Google Scholar
• Paquette M, Bernard S, Hegele RA, et al. Chylomicronemia: differences between familial chylomicronemia syndrome and multifactorial chylomicronemia. Atherosclerosis. 2019 Apr 01;283:137–142.
   PubMed Web of Science ®Google Scholar
• Dron JS, Wang J, Cao H, et al. Severe hypertriglyceridemia is primarily polygenic. J Clin Lipidol. 2019;13(1):80–88.
   PubMed Web of Science ®Google Scholar
• Hegele RA, Ginsberg HN, Chapman MJ, et al. The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. Lancet Diabetes Endocrinol. 2014;2(8):655–666.
   PubMed Web of Science ®Google Scholar
• The L. Diabetes: a dynamic disease. Lancet. 2017 Jul 03;389(10085):2163.
   PubMed Web of Science ®Google Scholar
• Smellie WS. Hypertriglyceridaemia in diabetes. Bmj. 2006 Dec 16;333(7581):1257–1260.
   PubMedGoogle Scholar
• Taskinen MR, Boren J. New insights into the pathophysiology of dyslipidemia in type 2 diabetes. Atherosclerosis. 2015 Apr;239(2):483–495.
   PubMed Web of Science ®Google Scholar
• Chan DC, Watts GF. Dyslipidaemia in the metabolic syndrome and type 2 diabetes: pathogenesis, priorities, pharmacotherapies. Expert Opin Pharmacother. 2011 Jan;12(1):13–30.
   PubMed Web of Science ®Google Scholar
• Murphy MJ, Sheng X, MacDonald TM, et al. Hypertriglyceridemia and acute pancreatitis. JAMA Intern Med. 2013 Jan 28;173(2):162–164.
   PubMed Web of Science ®Google Scholar
• Valdivielso P, Ramírez-Bueno A, Ewald N. Current knowledge of hypertriglyceridemic pancreatitis. Eur J Intern Med. 2014 Oct 01;25(8):689–694.
   PubMed Web of Science ®Google Scholar
• Pedersen SB, Langsted A, Nordestgaard BG. Nonfasting mild-to-moderate hypertriglyceridemia and risk of acute pancreatitis. JAMA Intern Med. 2016;176(12):1834–1842.
   PubMed Web of Science ®Google Scholar
• Mach F, Baigent C, Catapano AL, et al. ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J. 2020;41(1):111-188.
   PubMed Web of Science ®Google Scholar
• Scott R, O’Brien R, Fulcher G, et al. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care. 2009;32(3):493–498.
   PubMed Web of Science ®Google Scholar
• Group AS, Ginsberg HN, Elam MB, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1563–1574.
   PubMed Web of Science ®Google Scholar
• Robins SJ, Collins D, Wittes JT, et al. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. Jama. 2001 Mar 28;285(12):1585–1591.
   PubMed Web of Science ®Google Scholar
• The Bezafibrate Infarction Prevention (BIP) Study, The BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. Circulation. 2000 Jul 4;102(1):21–27.
   PubMed Web of Science ®Google Scholar
• Manninen V, Tenkanen L, Koskinen P, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation. 1992 Jan;85(1):37–45.
   PubMed Web of Science ®Google Scholar
• Meade T, Zuhrie R, Cook C, et al. Bezafibrate in men with lower extremity arterial disease: randomised controlled trial. Bmj. 2002 Nov 16;325(7373):1139.
   PubMed Web of Science ®Google Scholar
• Davidson MH. Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions. Expert Opin Drug Saf. 2006 Jan 01;5(1):145–156.
   PubMed Web of Science ®Google Scholar
• Fruchart JC. Pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor alpha modulator for management of atherogenic dyslipidaemia. Cardiovasc Diabetol. 2017 Oct 4;16(1):124.
   PubMedGoogle Scholar
• Ishibashi S, Yamashita S, Arai H, et al. Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial. Atherosclerosis. 2016 Jun 01;249:36–43.
   PubMed Web of Science ®Google Scholar
• Ishibashi S, Arai H, Yokote K, et al. Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: results from a 24-week, randomized, double blind, active-controlled, phase 3 trial. J Clin Lipidol. 2018 Jan 01;12(1):173–184.
   PubMed Web of Science ®Google Scholar
• Arai H, Yamashita S, Yokote K, et al. Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), in combination with statin treatment: two randomised, double-blind, placebo-controlled clinical trials in patients with dyslipidaemia. Atherosclerosis. 2017 Jun 01;261:144–152.
   PubMed Web of Science ®Google Scholar
• Araki E, Yamashita S, Arai H, et al. Effects of pemafibrate, a novel selective PPARα modulator, on lipid and glucose metabolism in patients with type 2 diabetes and hypertriglyceridemia: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care. 2018;41(3):538–546.
   PubMed Web of Science ®Google Scholar
• Pradhan AD, Paynter NP, Everett BM, et al. Rationale and design of the pemafibrate to reduce cardiovascular outcomes by reducing triglycerides in patients with diabetes (PROMINENT) study. Am Heart J. 2018 Dec;206:80–93.
   PubMed Web of Science ®Google Scholar
• Abdelhamid AS, Brown TJ, Brainard JS, et al. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2018 Jul 18;7:Cd003177.
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2018;380(1):11–22.
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Miller M, Brinton EA, et al. REDUCE-IT USA. Circulation. 2020;141(5):367–375.
   PubMed Web of Science ®Google Scholar
• Kastelein JJP, Stroes ESG. FISHing for the miracle of eicosapentaenoic acid. N Engl J Med. 2018;380(1):89–90.
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Lincoff AM, Bash D, et al. Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: rationale and design of the STRENGTH trial. Clin Cardiol. 2018 Oct;41(10):1281–1288.
   PubMed Web of Science ®Google Scholar
• Kawakami A, Aikawa M, Libby P, et al. Apolipoprotein CIII in apolipoprotein B lipoproteins enhances the adhesion of human monocytic cells to endothelial cells. Circulation. 2006 Feb 7;113(5):691–700.
   PubMed Web of Science ®Google Scholar
• Sacks FM. The crucial roles of apolipoproteins E and C-III in apoB lipoprotein metabolism in normolipidemia and hypertriglyceridemia. Curr Opin Lipidol. 2015;26(1):56–63.
   PubMed Web of Science ®Google Scholar
• Taskinen M-R, Packard CJ, Borén J. Emerging evidence that ApoC-III inhibitors provide novel options to reduce the residual CVD. Curr Atheroscler Rep. 2019 May 20;21(8):27.
   PubMed Web of Science ®Google Scholar
• Brown WV, Levy RI, Fredrickson DS. Studies of the proteins in human plasma very low density lipoproteins. J Biol Chem. 1969;244(20):5687–5694.
   PubMed Web of Science ®Google Scholar
• Ginsberg HN, Le NA, Goldberg IJ, et al. Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo. J Clin Invest. 1986 Nov 01;78(5):1287–1295.
   PubMed Web of Science ®Google Scholar
• Boren J, Watts GF, Adiels M, et al. Kinetic and related determinants of plasma triglyceride concentration in abdominal obesity: multicenter tracer kinetic study. Arterioscler Thromb Vasc Biol. 2015 Oct;35(10):2218–2224.
   PubMed Web of Science ®Google Scholar
• Gordts PLSM, Nock R, Son N-H, et al. ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors. J Clin Invest. 2016 Aug 01;126(8):2855–2866.
   PubMed Web of Science ®Google Scholar
• Sundaram M, Zhong S, Bou Khalil M, et al. Expression of apolipoprotein C-III in McA-RH7777 cells enhances VLDL assembly and secretion under lipid-rich conditions. J Lipid Res. 2010 Jan;51(1):150–161.
   PubMed Web of Science ®Google Scholar
• Qin W, Sundaram M, Wang Y, et al. Missense mutation in APOC3 within the C-terminal lipid binding domain of human ApoC-III results in impaired assembly and secretion of triacylglycerol-rich very low density lipoproteins: EVIDENCE THAT ApoC-III PLAYS A MAJOR ROLE IN THE FORMATION OF LIPID PRECURSORS WITHIN THE MICROSOMAL LUMEN. J Biol Chem. 2011 August 5;286(31):27769–27780.
   PubMed Web of Science ®Google Scholar
• Adiels M, Taskinen MR, Bjornson E, et al. Role of apolipoprotein C-III overproduction in diabetic dyslipidaemia. Diabetes Obes Metab. 2019 Aug;21(8):1861–1870.
   PubMed Web of Science ®Google Scholar
• Pollin TI, Damcott CM, Shen H, et al. A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection. Science (New York, NY). 2008;322(5908):1702–1705.
   Google Scholar
• Jørgensen AB, Frikke-Schmidt R, Nordestgaard BG, et al. Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med. 2014;371(1):32–41.
   PubMed Web of Science ®Google Scholar
• TG and HDL Working Group of the Exome Sequencing Project, National Heart, Lung, and Blood Institute, Crosby J. Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med. 2014;371(1):22–31.
   PubMed Web of Science ®Google Scholar
• Cohen Jonathan C, Stender S, Hobbs Helen H. APOC3, coronary disease, and complexities of mendelian randomization. Cell Metab. 2014 Sep 02;20(3):387–389.
   PubMed Web of Science ®Google Scholar
• Wyler von Ballmoos MC, Haring B, Sacks FM. The risk of cardiovascular events with increased apolipoprotein CIII: A systematic review and meta-analysis. J Clin Lipidol. 2015 Jul-Aug;9(4):498–510.
   PubMed Web of Science ®Google Scholar
• Lee SJ, Campos H, Moye LA, et al. LDL containing apolipoprotein CIII is an independent risk factor for coronary events in diabetic patients. Arterioscler Thromb Vasc Biol. 2003 May 1;23(5):853–858.
   PubMed Web of Science ®Google Scholar
• Morton AM, Koch M, Mendivil CO, et al. Apolipoproteins E and CIII interact to regulate HDL metabolism and coronary heart disease risk. JCI Insight. 2018 Feb 22;3(4). DOI: 10.1172/jci.insight.98045.
   Web of Science ®Google Scholar
• Talayero B, Wang L, Furtado J, et al. Obesity favors apolipoprotein E- and C-III-containing high density lipoprotein subfractions associated with risk of heart disease. J Lipid Res. 2014 October 1;55(10):2167–2177.
   PubMed Web of Science ®Google Scholar
• Kole R, Krainer AR, Altman S. RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat Rev Drug Discov. 2012 Feb 01;11(2):125–140.
   PubMed Web of Science ®Google Scholar
• Graham MJ, Lee RG, Bell TA, et al. Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans. Circ Res. 2013;112(11):1479–1490.
   PubMed Web of Science ®Google Scholar
• Gaudet D, Brisson D, Tremblay K, et al. Targeting APOC3 in the familial chylomicronemia syndrome. N Engl J Med. 2014;371(23):2200–2206.
   PubMed Web of Science ®Google Scholar
• Gaudet D, Alexander VJ, Baker BF, et al. Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia. N Engl J Med. 2015;373(5):438–447.
   PubMed Web of Science ®Google Scholar
• Digenio A, Dunbar RL, Alexander VJ, et al. Antisense-mediated lowering of plasma apolipoprotein C-III by volanesorsen improves dyslipidemia and insulin sensitivity in type 2 diabetes. Diabetes Care. 2016;39(8):1408–1415.
   PubMed Web of Science ®Google Scholar
• Gaudet D, Digenio A, Alexander VJ, et al. The APPROACH study: a randomized, double-blind, placebo-controlled, phase 3 study of volanesorsen administered subcutaneously to patients with familial chylomicronemia syndrome (FCS). J Clin Lipidol. 2017;11(3):814–815.
   Google Scholar
• Gouni-Berthold I, Alexander V, Digenio A, et al. Apolipoprotein C-III inhibition with volanesorsen in patients with hypertriglyceridemia (COMPASS): a randomized, double-blind, placebo-controlled trial. J Clin Lipidol. 2017;11(3):794–795.
   Google Scholar
• Gelrud A, Digenio A, Alexander VJ, et al. Treatment with volanesorsen (VLN) reduced triglycerides and pancreatitis in patients with FCS and sHTG vs placebo: results of the APPROACH and COMPASS studies. Atherosclerosis Suppl. 2018;32:157.
   Web of Science ®Google Scholar
• Macchi C, Sirtori CR, Corsini A, et al. A new dawn for managing dyslipidemias: the era of rna-based therapies. Pharmacol Res. 2019 Dec 01;150:104413.
   PubMed Web of Science ®Google Scholar
• Alexander VJ, Xia S, Hurh E, et al., N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels. Eur Heart J. 40(33): 2785–2796. 2019. .
   PubMed Web of Science ®Google Scholar
• Wolska A, Lo L, Sviridov DO, et al. A dual apolipoprotein C-II mimetic-apolipoprotein C-III antagonist peptide lowers plasma triglycerides. Sci Transl Med. 2020 Jan 29;12(528). DOI: 10.1126/scitranslmed.aaw7905.
   PubMed Web of Science ®Google Scholar
• Huynh K. Dual apoC-II mimetic and apoC-III antagonist for hypertriglyceridaemia. Nat Rev Cardiol. 2020 Apr 01;17(4): 201.
   Web of Science ®Google Scholar
• Conklin D, Gilbertson D, Taft DW, et al. Identification of a mammalian angiopoietin-related protein expressed specifically in liver. Genomics. 1999 Dec 15;62(3):477–482.
   PubMed Web of Science ®Google Scholar
• Musunuru K, Pirruccello JP, Do R, et al. Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia. N Engl J Med. 2010;363(23):2220–2227.
   PubMed Web of Science ®Google Scholar
• Stitziel NO, Khera AV, Wang X, et al. ANGPTL3 deficiency and protection against coronary artery disease. J Am Coll Cardiol. 2017;69(16):2054–2063.
   PubMed Web of Science ®Google Scholar
• Biterova E, Esmaeeli M, Alanen HI, et al. Structures of Angptl3 and Angptl4, modulators of triglyceride levels and coronary artery disease. Sci Rep. 2018 Apr 30;8(1):6752.
   PubMedGoogle Scholar
• Kristensen KK, Leth-Espensen KZ, Mertens HDT, et al. Unfolding of monomeric lipoprotein lipase by ANGPTL4: insight into the regulation of plasma triglyceride metabolism. Proc Natl Acad Sci U S A. 2020 Feb 25;117(8):4337–4346.
   PubMed Web of Science ®Google Scholar
• Shan L, Yu XC, Liu Z, et al. The angiopoietin-like proteins ANGPTL3 and ANGPTL4 inhibit lipoprotein lipase activity through distinct mechanisms. J Biol Chem. 2009 Jan 16;284(3):1419–1424.
   PubMed Web of Science ®Google Scholar
• Haller JF, Mintah IJ, Shihanian LM, et al. ANGPTL8 requires ANGPTL3 to inhibit lipoprotein lipase and plasma triglyceride clearance. J Lipid Res. 2017 June 1;58(6):1166–1173.
   PubMed Web of Science ®Google Scholar
• Kovrov O, Kristensen KK, Larsson E, et al. On the mechanism of angiopoietin-like protein 8 for control of lipoprotein lipase activity. J Lipid Res. 2019;27:2019.
   Google Scholar
• Kersten S. New insights into angiopoietin-like proteins in lipid metabolism and cardiovascular disease risk. Curr Opin Lipidol. 2019;30(3):205–211.
   PubMed Web of Science ®Google Scholar
• Wang Y, Gusarova V, Banfi S, et al. Inactivation of ANGPTL3 reduces hepatic VLDL-triglyceride secretion. J Lipid Res. 2015 Jul;56(7):1296–1307.
   PubMed Web of Science ®Google Scholar
• Dewey FE, Gusarova V, O’Dushlaine C, et al. Inactivating variants in ANGPTL4 and risk of coronary artery disease. N Engl J Med. 2016 Mar 24;374(12):1123–1133.
   PubMed Web of Science ®Google Scholar
• Stitziel NO, Stirrups KE, Masca NG, et al. Coding variation in ANGPTL4, LPL, and SVEP1 and the risk of coronary disease. N Engl J Med. 2016 Mar 24;374(12):1134–1144.
   PubMed Web of Science ®Google Scholar
• Lichtenstein L, Mattijssen F, de Wit NJ, et al. Angptl4 protects against severe proinflammatory effects of saturated fat by inhibiting fatty acid uptake into mesenteric lymph node macrophages. Cell Metab. 2010 Dec 1;12(6):580–592.
   PubMed Web of Science ®Google Scholar
• Dewey FE, Gusarova V, Dunbar RL, et al. Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease. N Engl J Med. 2017;377(3):211–221.
   PubMed Web of Science ®Google Scholar
• Gaudet D, Gipe DA, Pordy R, et al., ANGPTL3 inhibition in homozygous familial hypercholesterolemia. N Engl J Med. 377(3): 296–297. 2017. .
   PubMed Web of Science ®Google Scholar
• Graham MJ, Lee RG, Brandt TA, et al., Cardiovascular and metabolic effects of ANGPTL3 antisense oligonucleotides. N Engl J Med. 377(3): 222–232. 2017. .
   PubMed Web of Science ®Google Scholar
• Witztum JL, Gaudet D, Freedman SD, et al. Volanesorsen and triglyceride levels in familial chylomicronemia syndrome. N Engl J Med. 2019;381(6):531–542.
   PubMed Web of Science ®Google Scholar